Nina has often stated that Dimerix is fully funded for the phase 3 trials and that more deals are in the pipeline prior to phase 3 completion.
There is confidence in the science in the existing agreements. And researching the science and scientists involved - it further enhances that confidence.
DMX-200 (repagermanium), reduces the amount of proteinuria (when protein from your blood collects in your urine) and slows the decline of kidney function, when taken in addition to a medicine called an angiotensin II receptor blocker (ARB). An ARB is a very commonly used medicine in FSGS.
More agreement(s) could drop at any stage.
https://investors.dimerix.com/FormBuilder/_Resource/_module/WRxy8W0jV0SarmkfnUde8g/docs/DXB_A_Rare_Opportunit_2024.pdf
The above is a recent analysis performed by EUROZ HARTLEYS. It clarifies several points including:
1) The safety and efficacy of DMX 200 i.e.Last month the trial was de-risked when DXB announced DMX-200 had passed the efficacy futility analysis, indicating it is performing better than placebo. Importantly, this analysis represents a patient cohort nearly 10x larger than that of the phase 2 trial.
2) We estimate there is a +A$5 billion total addressable market (TAM) for DMX-200 in the treatment of FSGS.
3) Licensing Deal ⁄ Commercial Validation - DXB executed a major $230m licensing deal last year with European speciality pharma company Advanz Pharma, covering the European Economic Area, and other select regions. The deal could yield up to $220m in milestone payments for DXB, plus royalties of 15-20% on net sales. Additionally, DXB has received multiple non-binding term sheets for global and regional licensing deals, with a USA deal poised to be a major catalyst.
4) Fully Funded - The company is fully funded through to the completion of its phase 3 trial in FSGS with circa $38.6m in pro-forma cash, and an additional $7.7m of options in the money. Moreover, this cash could be supplemented by future licensing deals.
I am accumulating DXB shares - just like I accumulated NEU shares from $1.71 to $18.90 just last week (average $4)....
When you research DXB - it ticks all the boxes. DYOR. Start with Google! GLTAH.
- Forums
- ASX - By Stock
- DXB
- DXB Media thread.
DXB Media thread., page-167
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.0¢ |
Change
-0.035(6.67%) |
Mkt cap ! $280.5M |
Open | High | Low | Value | Volume |
52.0¢ | 52.0¢ | 48.0¢ | $1.688M | 3.373M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 59399 | 48.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.0¢ | 758 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 59399 | 0.485 |
20 | 400063 | 0.480 |
7 | 231558 | 0.475 |
5 | 103447 | 0.470 |
4 | 51900 | 0.465 |
Price($) | Vol. | No. |
---|---|---|
0.490 | 758 | 1 |
0.495 | 61865 | 7 |
0.500 | 79009 | 5 |
0.505 | 52129 | 6 |
0.510 | 28511 | 2 |
Last trade - 13.35pm 03/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online